Impact of human recombinant erythropoietin on plasminogen activator inhibitor, and protein C and S activity.
Steffensen
G
G
Aunsholt
N A
NA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D015849:Plasminogen Inactivators / Q000097:blood*; D011486:Protein C / Q000187:drug effects / Q000378:metabolism*; D017293:Protein S / Q000187:drug effects / Q000378:metabolism*; D011994:Recombinant Proteins; D006435:Renal Dialysis
D006454:Hemoglobins; D015849:Plasminogen Inactivators; D011486:Protein C; D017293:Protein S; D011994:Recombinant Proteins; D004921:Erythropoietin